A Bayesian Reanalysis of the CULPRIT-SHOCK Trial.
Christian JungBernhard WernlyMaryna MasyukMalte KelmAnne FreundJanine PössSteffen DeschSteffen SchneiderIbrahim AkinSabrina SchlesingerBenedikt SchrageUwe ZeymerHolger ThielePublished in: European heart journal. Acute cardiovascular care (2024)
Our Bayesian reanalysis provides intuitive insights by quantifying probabilities of treatment effect sizes, offering further evidence favoring the culprit-lesion-only PCI strategy in AMI patients with cardiogenic shock and multivessel disease. The analysis demonstrates a high probability of overall benefit, with a notable chance of achieving a minimally clinically important difference, particularly in specific subgroups. These findings not only support the consideration of culprit-lesion-only PCI in certain patient populations but also underscore the need for careful risk-benefit assessment. Furthermore, our hypothesis-generating subgroup analyses, which show varying probabilities of achieving MCID, illuminate promising avenues for future targeted investigations in this critical patient population.
Keyphrases
- percutaneous coronary intervention
- acute myocardial infarction
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- coronary artery disease
- case report
- acute coronary syndrome
- coronary artery bypass grafting
- antiplatelet therapy
- phase iii
- atrial fibrillation
- cancer therapy
- drug delivery
- current status
- open label